Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Minority Interest (2021 - 2026)

Rani Therapeutics Holdings' Minority Interest history spans 6 years, with the latest figure at $7.1 million for Q1 2026.

  • On a quarterly basis, Minority Interest rose 411.3% to $7.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.1 million, a 411.3% increase, with the full-year FY2025 number at $8.5 million, up 466.42% from a year prior.
  • Minority Interest came in at $7.1 million for Q1 2026, down from $8.5 million in the prior quarter.
  • The five-year high for Minority Interest was $57.3 million in Q1 2022, with the low at -$4.1 million in Q3 2025.
  • Historically, Minority Interest has averaged $17.3 million across 5 years, with a median of $8.5 million in 2025.
  • Peak annual rise in Minority Interest hit 466.42% in 2025, while the deepest fall reached 254.92% in 2025.
  • Year by year, Minority Interest stood at $37.1 million in 2022, then crashed by 66.14% to $12.6 million in 2023, then plummeted by 88.07% to $1.5 million in 2024, then soared by 466.42% to $8.5 million in 2025, then decreased by 16.04% to $7.1 million in 2026.
  • Business Quant data shows Minority Interest for RANI at $7.1 million in Q1 2026, $8.5 million in Q4 2025, and -$4.1 million in Q3 2025.